Healthy Volunteers Clinical Trial
Official title:
A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Adult Male Subjects
Verified date | May 2019 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the mass balance, routes of elimination and characterize the metabolic profiles of a single intravenous dose of [14C]-TAK-954, identify major circulating and excreted metabolites. This study will also determine the single-dose PK of total radioactivity, TAK-954 and its metabolites where possible.
Status | Completed |
Enrollment | 6 |
Est. completion date | June 1, 2018 |
Est. primary completion date | June 1, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Be a man aged 18 to 55 years, inclusive, at the screening visit. 2. Have a body mass index (BMI) greater than or equal to (>=) 18 and less than or equal to (<=) 30 kilogram per square meter (kg/m^2) and a body weight greater than (>) 50 kilogram (kg) at the screening visit. 3. Be a nonsmoker who has not used tobacco- or nicotine-containing products (example, nicotine patch) for at least 6 months before administration of the initial dose of trial drug. 4. Meet the following birth control requirements: - Is a male participant who is sterile or agrees to use an appropriate method of contraception, including a condom, from the first dose of study drug until 30 days after the last dose of study drug. No restrictions are required for a vasectomized male participant provided that the participant is at least 1 year postbilateral vasectomy procedure before the first dose of study drug. A male participant whose vasectomy procedure was performed less than 1 year before the first dose of study drug must follow the same restrictions as a nonvasectomized man. Appropriate documentation of surgical procedures should be provided. - Is a male participant who agrees to not donate sperm from trial drug administration on the first day of the first dose until 30 days after the last dose of study drug. Exclusion Criteria: 1. Has total 14C radioactivity measured by accelerator mass spectrometry in plasma (during screening) exceeding 14C/12C ratio 1.1E-12. 2. Participated in any study with a radiation dose above 0.1 millibecquerel (MBq) or radiation burden above 0.1 millisievert (mSv) within 1 year before screening. 3. Was exposed to significant radiation (example, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months before check-in. 4. Irregular defecation pattern (less than once per 2 days). 5. Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to beer 354 milliliter [mL]/12 ounce [oz], wine 118 mL/4 oz, or distilled spirits 29.5 mL/1 oz). 6. Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day. 7. Has a substance abuse disorder. |
Country | Name | City | State |
---|---|---|---|
Netherlands | PRAHS | Groningen |
Lead Sponsor | Collaborator |
---|---|
Millennium Pharmaceuticals, Inc. |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cumulative Percentage of Administered Radioactivity Recovered in Urine | Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose | ||
Primary | Cumulative Percentage of Administered Radioactivity Recovered in Feces | Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose | ||
Primary | Cumulative Percentage of Radioactivity in Urine and Feces Combined | Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose | ||
Primary | Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine and Feces Combined | Percentage of dose recovered for TAK-954 and its metabolites derived from 0-168 hour sampling was normalized for 100% recovery. | Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose | |
Primary | Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine | Percentage of dose recovered for TAK-954 and its metabolites derived from 0-168 hour sampling was normalized for 100% recovery. | Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose | |
Primary | Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Feces | Percentage of dose recovered for TAK-954 and its metabolites derived from 0-168 hour sampling was normalized for 100% recovery. | Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose | |
Primary | Mean Percent of Total Radioactivity in Plasma for TAK-954 and TAK-954 Metabolites | Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose | ||
Primary | Cumulative Percentage of Dose Excreted in Urine for TAK-954 | Day 1 pre-dose and at multiple time points (up to 264, 312, and 336 hours) post-dose | ||
Primary | Cumulative Percentage of Dose Excreted in Feces for TAK-954 | The cumulative percentage of dose excreted in feces as TAK-954 derived from 0-168 hour sampling was normalized for 100% recovery. | Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose | |
Primary | Mean Concentration of Total Radioactivity in Whole Blood and Plasma [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Cmax: Maximum Observed Plasma and Whole Blood Concentrations of Radioactivity for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Cmax: Maximum Observed Plasma Concentration for TAK-954 and TAK-954 Metabolites | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | AUClast: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to the Time of the Last Quantifiable Radioactivity for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 and TAK-954 Metabolites | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | AUC8: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to Infinity for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | AUC8: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 and TAK-954 Metabolites | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Tmax: Time to Reach the Maximum Plasma and Whole Blood Radioactivity for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-954 and TAK-954 Metabolites | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | t1/2z: Terminal Disposition Phase Half-life of Radioactivity in Plasma and Whole Blood for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | t1/2z: Terminal Disposition Phase Half-life in Plasma for TAK-954 and TAK-954 Metabolites | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | CL: Total Clearance After Intravenous Administration for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | CL: Total Clearance of TAK-954 After Intravenous Administration of [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Aet Urine: Amount of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Aet Urine: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Aet Feces: Amount of Total Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Fet Urine: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Fet Urine: Fraction of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Primary | Fet Feces: Fraction of Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Secondary | Ratio of Total Radioactivity in Whole Blood to Plasma | Day 1 pre-dose and at multiple time points (up to 264 hours) post-dose | ||
Secondary | Ratio of AUC8: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 to Total Radioactivity in Plasma TAK-954 | Day 1 pre-dose and at multiple time points (up to 336 hours) post-dose | ||
Secondary | Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) | Baseline up to Day 31 | ||
Secondary | Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of [14C]-TAK-954 | Baseline up to Day 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |